Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes

Leukemia

Volumn 12, Issue 12, 1998, Pages 2006-2014

  Pongers Willemse, M J ^a   Verhagen, O J H M ^b   Tibbe, G J M ^a   Wijkhuijs, A J M ^a   De Haas, V ^b   Roovers, E ^c   Van Der School, C E ^b   Van Dongen, J J M ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c PE Biosystems   (Netherlands)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

ALL; Immunoglobulin genes; Junctional region; MRD; Quantification; RQ PCR; T cell receptor genes

Indexed keywords

FLUORESCENT DYE; IMMUNOGLOBULIN RECEPTOR; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BIOTECHNOLOGY; CASE REPORT; CHILDHOOD LEUKEMIA; GENE REARRANGEMENT; HUMAN; HUMAN CELL; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; T LYMPHOCYTE RECEPTOR GENE;

EID: 0031760453     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401246     Document Type: Article

References (26)

1. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995; 85: 1151-1168.
2. Veerman AJ, Hählen K, Kamps WA, Van Leeuwen EF, De Vaan GA, Solbu G, Suciu S, Van Wering ER, Van der Does-Van den Berg A. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 1996; 14: 911-918.
3. Pui CH, Evans WE. Drug therapy: acute lymphoblastic leukemia. New Engl J Med 1998; 339: 605-615.
4. Bartram CR. Detection of minimal residual leukemia by the polymerase chain reaction: potential implications for therapy. Clin Chim Acta 1993; 217: 75-83.
5. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85: 1416-1434.
6. Van Dongen JJM, Szczepański T, De Bruijn MAC, Van den Beemd MWM, De Bruin-Versteeg S, Wijkhuijs JM, Tibbe GJM, Van Gastel-Mol EJ, Groeneveld K, Hooijkaas H. Detection of minimal residual disease in acute leukemia patients. Cytokin Mol Ther 1996; 2: 121-133.
7. Wasserman R, Galili N, Ito Y, Silber JH, Reichard BA, Shane S, Womer RB, Lange B, Rovera G. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 1992; 10: 1879-1888.
8. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H er al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343: 196-200.
9. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, Rubnitz JE, Rivera GK, Sandlund JT, Pui CH, Campana D. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351: 550-554.
10. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E, Nelken B, Fournier M, Boutard P, Lebrun E, Mechinaud F, Garand R, Robert A, Dastugue N, Plouvier E, Racadot E, Ferster A, Gyselinck J, Fenneteau O, Duval M, Solbu G, Manel AM. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. New Engl J Med 1998; 339: 591-598.
11. Van Dongen JJM, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig W-D, Basso G, De Bruijn MAC, Cazzaniga G, Hettinger K, Van der Does-van den Berg A, Hop WCJ, Riehm H, Bartram CR. Prognostic value of minimal residual disease in childhood acute lymphoblastic leukemia. A prospective study of the International BFM Study Group. Lancet 1998 (in press).
12. Steenbergen EJ, Verhagen OJ, van Leeuwen EF, Van den Berg H, Behrendt H, Slater RM, Von dem Borne AE, Van der School CE. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Leukemia 1995; 9: 1726-34.
13. Foroni L, Coyle LA, Papaioannou M, Yaxley JC, Sinclair MF, Chim JS, Cannell P, Secker-Walker LM, Mehta AB, Prentice HG, Hoffbrand AV. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response. Leukemia 1997; 11: 1732-1741.
14. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988; 334: 395-402.
15. Van Dongen JJM, Wolvers-Tettero ILM. Analysis of immunoglobulin and T cell receptor genes. Part I: basic and technical aspects. Clin Chim Acta 1991; 198: 1-91.
16. Beishuizen A, Hählen K, Hagemeijer A, Verhoeven MA, Hooijkaas H, Adriaansen HJ, Wolvers-Tettero ILM, Van Wering ER, Van Dongen JJM. Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B cell origin. Leukemia 1991; 5: 657-667.
17. Kitchingman GR. Immunoglobulin heavy chain gene VH-D functional diversity at diagnosis in patients with acute lymphoblastic leukemia. Blood 1993; 81: 775-782.
18. Ghali DW, Panzer S, Fischer S, Argyriou-Tirita A, Haas OA, Kovar H, Gadner H, Panzer-Grümayer ER. Heterogeneity of the T cell receptor delta gene indicating subclone formation in acute precursor B cell leukemias. Blood 1995; 85: 2795-2801.
19. Steenbergen EJ, Verhagen OJ, Van den Berg H, Van Leeuwen EF, Behrendt H, Slater RR, Von dem Borne AE, Van der School CE. Rearrangement status of the malignant cell determines type of secondary IgH rearrangement (V-replacement or V to DJ joining) in childhood B precursor acute lymphoblastic leukemia. Leukemia 1997; 11: 1258-1265.
20. Steenbergen EJ, Verhagen OJ, Van Leeuwen EF, Von dem Borne AE, van der School CE. Distinct ongoing lg heavy chain rearrangement processes in childhood B-precursor acute lymphoblastic leukemia. Blood 1993; 82: 581-589.
21. Beishuizen A, Verhoeven MA, Van Wering ER, Hählen K, Hooijkaas H, Van Dongen JJM. Analysis of lg and T cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 1994; 83: 2238-2247.
22. Taylor JJ, Rowe D, Kylefjord H, Chessells J, Katz F, Proctor SJ, Middleton PC. Characterisation of non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia. Leukemia 1994; 8: 60-66.
23. Seriu T, Hansen-Hagge TE, Erz DH, Bartram CR. Improved detection of minimal residual leukemia through modifications of polymerase chain reaction analyses based on clonospecific T cell receptor junctions. Leukemia 1995; 9: 316-320.
24. Steenbergen EJ, Verhagen OJ, Van Leeuwen EF, Van den Berg H, Behrendt H, Von dem Borne AE, Van der School CE. IgH/TCR delta PCR oligonucleotide liquid hybridizalion, a fast and sensitive assay for monitoring minimal residual disease in childhood B-precursor ALL. Leukemia 1995; 9: 216-222.
25. Cross NC. Quantitative PCR techniques and applications. Br J Haematol 1995; 89: 693-697.
26. Cave H, Guidal C, Rohrlich P, Delfau MH, Broyart A, Lescoeur B, Rahimy C, Fenneteau O, Monplaisir N, d'Auriol L, Elion J, Vilmer E, Grandchamp B. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood 1994; 83: 1892-1902.